Back to Trial

Oracle Runs

Oracle findings and outcome history for Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder (NCT05423717).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 6:34 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Public readout is clearly positive for this exact Phase 2 trial. Idorsia announced positive top-line results for NCT05423717, citing a statistically significant dose-dependent improvement in total sleep time plus clinically meaningful multi-measure benefits and placebo-like safety; trade coverage framed it as a Phase 2 win.

Sources
Sponsoridorsia.com3/30/26
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder

Sponsor says NCT05423717 had positive top-line Phase 2 results: statistically significant dose-dependent improvement in total sleep time, clinically meaningful sleep gains, and placebo-like safety/tolerability.

View source
Web Searchfiercepharma.com3/30/26
Idorsia eyes pediatric insomnia use with midstage trial win for sleep med Quviviq

Independent trade coverage described the pediatric daridorexant study as a Phase 2 trial win after the company reported positive results.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted98% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Public readout is clearly positive for this exact Phase 2 trial. Idorsia announced positive top-line results for NCT05423717, citing a statistically significant dose-dependent improvement in total sleep time plus clinically meaningful multi-measure benefits and placebo-like safety; trade coverage framed it as a Phase 2 win.

Found Apr 1, 2026, 6:34 PMOutcome date Mar 30, 2026, 12:00 AMReviewed Apr 1, 2026, 6:36 PM
Sponsoridorsia.comMar 30, 2026, 12:00 AM
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder
Sponsor says NCT05423717 had positive top-line Phase 2 results: statistically significant dose-dependent improvement in total sleep time, clinically meaningful sleep gains, and placebo-like safety/tolerability.
Web Searchfiercepharma.comMar 30, 2026, 12:00 AM
Idorsia eyes pediatric insomnia use with midstage trial win for sleep med Quviviq
Independent trade coverage described the pediatric daridorexant study as a Phase 2 trial win after the company reported positive results.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 6:36 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)98% confidenceReviewed Apr 1, 2026, 6:36 PM

Public readout is clearly positive for this exact Phase 2 trial. Idorsia announced positive top-line results for NCT05423717, citing a statistically significant dose-dependent improvement in total sleep time plus clinically meaningful multi-measure benefits and placebo-like safety; trade coverage framed it as a Phase 2 win.